Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728258 · ClinicalTrials.gov registry record · Phase 2
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase 2 study, sponsored by NRG Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02728258 is a Phase 2 study that has completed, run by NRG Oncology. The registered enrollment target is 11 participants.
The verdict
NCT02728258, a Phase 2 study, has completed, sponsored by NRG Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This phase II trial studies how well copanlisib works in treating patients with endometrial cancer that has not decreased or disappeared, and the cancer may still be in the body despite treatment (persistent) or has come back (recurrent). Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Copanlisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-09-16 |
| Est. Completion | 2020-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02728258
The ClinicalTrials.gov registry entry for NCT02728258 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02728258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02728258 about?
NCT02728258 is a clinical study titled "Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer". This phase II trial studies how well copanlisib works in treating patients with endometrial cancer that has not decreased or disappeared, and the cancer may still be in the body despite treatment (persistent) or has come back (recurrent). Copanlisib may stop the growth of tumor cells by blocking som...
What is the current status of trial NCT02728258?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2016-09-16. Estimated completion is 2020-02-14.
What interventions are being tested in trial NCT02728258?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Copanlisib (DRUG).
Who is sponsoring clinical trial NCT02728258?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.